NasdaqCM - Nasdaq Real Time Price USD

MEI Pharma, Inc. (MEIP)

Compare

1.8700

+0.0300

+(1.63%)

At close: 4:00:00 PM EDT

2.2000

+0.33

+(17.65%)

After hours: 6:05:03 PM EDT

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

SAN DIEGO, February 12, 2025--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ended December 31, 2024.

Business Wire last month

MEIP
+1.63%
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

SAN DIEGO, November 12, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its quarter ended September 30, 2024.

Business Wire 4 months ago

MEIP
+1.63%
MEI Pharma Reports Fiscal Year End 2024 Cash Position

SAN DIEGO, September 19, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024.

Business Wire 6 months ago

MEIP
+1.63%
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

SAN DIEGO, August 12, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders.

Business Wire 7 months ago

MEIP
+1.63%
MEI Pharma to Consider Strategic Alternatives

SAN DIEGO, July 22, 2024--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process.

Business Wire 8 months ago

MEIP
+1.63%
7 Undervalued Biotech Stocks to Buy for Big-Time Returns

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price. Of course, the broader healthcare ecosystem offers a compelling narrative for market participants. As the Covid-19 pandemic demonstrated, no matter how advanced we become as a society, a microscopic virus can impose devastation. In order to protect individuals and communities at large, enterprises need a way to address di

InvestorPlace 9 months ago

MDXG

UTHR

MEIP
+1.63%
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

SAN DIEGO, May 09, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.

Business Wire 10 months ago

MEIP
+1.63%

Performance Overview

Return	MEIP	S&P 500 (^GSPC)
YTD	-23.98%	-8.81%
1-Year	-48.48%	+3.16%
3-Year	-77.29%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MEI Pharma, Inc. (MEIP)

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Fiscal Year End 2024 Cash Position

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

MEI Pharma to Consider Strategic Alternatives

7 Undervalued Biotech Stocks to Buy for Big-Time Returns

MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights

Performance Overview